The financials
LivaNova PLC by the numbers
LivaNova PLC (LIVN) reported revenue of $362M in Q1 2026 (quarter ended March 31, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 67% and net income of $22M (6.2% of revenue). For the full year FY2025, revenue was $1.39B (+11% year on year) and net income −$242M. Its largest segment in 2026-Q2 was Neuromodulation at $127M, 63% of the disclosed total, just ahead of Cardiopulmonary at 37%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $362M | $317M | +14% |
| Gross profit | $244M | $216M | +13% |
| Operating income | $41M | $49M | −15% |
| Net income | $22M | −$327M | to a profit |
| Diluted EPS | $0.40 | −$6.01 | to a profit |
| Operating | Revenue | Share |
|---|---|---|
| Neuromodulation | $127M | 63% |
| Cardiopulmonary | $73M | 37% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $199.3M (+7.9%)
Neuromodulation grew +8.0% year on yearCardiopulmonary +2.2% year on year
Segment Latestquarter on quarteryear on year
- Neuromodulation$126.6M$126.6MQoQ +9.7%year on year +8.0%+9.7%+8.0%
- Cardiopulmonary$72.8M$72.8MQoQ +5.1%year on year +2.2%+5.1%+2.2%